Dechra Pharmaceuticals (DPH)

 

DPH Share PerformanceMore

52 week high1,462.0 04/10/16
52 week low811.0 24/06/16
52 week change 234.0 (23.12%)
4 week volume2,805,225 09/11/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director Deals - Dechra Pharmaceuticals PLC (DPH)

Tony Rice, Non Executive Director, bought 120,000 shares in the company on the 2nd December 2016 at a price of 1247.00p...

Director/PDMR Shareholding

RNS Number: 9715Q Dechra Pharmaceuticals PLC 05 December 2016 5 December 2016 Dechra Pharmaceuticals PLC (Dechra or the Company) Notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs) Purchase of shares: Dechra Pharmaceuticals PLC announces that on 2 December 2016, Tony Rice purchasedthe sh...

Director/PDMR Shareholding

RNS Number: 5922Q Dechra Pharmaceuticals PLC 30 November 2016 30 November 2016 Dechra Pharmaceuticals PLC (Dechra or the Company) Notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs) Sale of shares: Dechra Pharmaceuticals PLC announces that on 30 November 2016, Ian Page and Tony Griffin...

Dechra options exercised

Dechra Pharmaceuticals directors Ian Page and Tony Griffin have exercised 124,375 and 32,849 nil cost share options respec...

Total Voting Rights

RNS Number: 4483Q Dechra Pharmaceuticals PLC 30 November 2016 30 November 2016 Dechra Pharmaceuticals PLC (Dechra or the Company) Total Voting Rights In conformity with DTR 5.6.1R, the Company notifies the market of the following: As at the date of this announcement, the Company's issued share capital consists of 93,038,928 ordinary shares with a n...

Exercise of LTIP options

RNS Number: 4797Q Dechra Pharmaceuticals PLC 29 November 2016 29 November 2016 Dechra Pharmaceuticals PLC (Dechra or the Company) Notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMR) and persons closely associated with them (PCA) Exercise of LTIP options: Dechra Pharmaceuticals PLC announ...

Additional Listing

RNS Number: 3489O Dechra Pharmaceuticals PLC 14 November 2016 14 November 2016 Dechra Pharmaceuticals PLC (Dechra or the Company) Additional Listing An application has been made to the Financial Conduct Authority and the London Stock Exchange for a total of 140,000 ordinary shares of 1 pence each (the "Shares") to be admitted to the Official List. T...

Appointment of Non-Executive Director

RNS Number: 7795O Dechra Pharmaceuticals PLC 09 November 2016 9 November 2016 Dechra Pharmaceuticals PLC (Dechra, Company or the Group) Board Appointment Appointment of Non-Executive Director Dechra is pleased to announce that Lawson Macartney has been appointed to the Board as Non-Executive Director with effect from 1 December 2016. D...

Fundamental DataMore

P/E ratio89
EPS14
Dividend yield1.482 %

Equity Research (DPH)

edison investment research
Dechra Pharmaceuticals plc
10/09/2015
Dechra Pharmaceuticals delivered FY15 revenue growth of 10% CER to £203.5m and EPS growth of 16.9% from 36.3p to 39.9p, with strong sales performances in its Companion Animal Products (CAP) segment,...
edison investment research
Dechra Pharmaceuticals plc
08/07/2015
Dechra Pharmaceuticals’ medium-term outlook is underpinned by a sharpened portfolio focus, new product launches and geographic expansion. Solid performances on these fronts in FY15 have overcome the...
edison investment research
Dechra Pharmaceuticals plc
29/04/2015
Dechra Pharmaceuticals has delivered another solid quarter with revenue growth up 6.0% (14.3% CER), resulting in nine-month growth of 6.6% (12.3% CER). Although boosted by phasing of pre-Easter...

Latest discussion posts More

  • Kate Burgess ...

    ... off of the FT wrote a good piece in her Small Talk column about Dechra in today's pink 'un. Overall highly favourable. Tabs for Fido and Dobbin are real money ...
    12-Sep-2016
    LK Hyman
  • panmure

    "Dechra has announced the receipt of FDA approval for the first registration ? a generic antibiotic ? delivered through Putney?s development pipeline since the acquisition of ...
    9-Sep-2016
    Sambram
  • Re: Well, them results all ...

    "Dechra has announced a US product launch from the Putney stable, an antibiotic for cats & dogs. This will be the first generic entrant into a $50m market currently controlled ...
    9-Sep-2016
    Sambram

Users' HoldingsMore

Users who hold Dechra Pharmaceuticals also hold..
NATIONAL GRID51%
DIAGEO41%
LLOYDS GRP.32%
SHIRE30%
PZ CUSSONS28%

Codes & Symbols

ISINGB0009633180
SymbolsDPH, LSE:DPH, DPH.L, DPH:LN, LON:DPH, XLON:DPH